Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: A single-centre database analysis

British Journal of Dermatology

Volumn 171, Issue 4, 2014, Pages 875-883

  Menting, S P ^a   Sitaram, A S ^a   Bonnerjee Van Der Stok, H M ^a   De Rie, M A ^a   Hooft, L ^b   Spuls, Ph I ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Dutch Cochrane Center   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CONTROLLED STUDY; DATA BASE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; SKINDEX 29 SCORE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; DRUG ADMINISTRATION; DRUG SUBSTITUTION; MIDDLE AGED; PROSPECTIVE STUDY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84936075056     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13001     Document Type: Article

References (26)

1. Papp KA, Griffiths CE, Gordon K, et al,. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.
2. Papp KA,. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
3. Rustin MH,. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167 (Suppl. 3): 3-11.
4. Brunasso AM, Puntoni M, Salvini C, et al,. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol 2011; 91: 44-9.
5. van Lümig PP, Driessen RJ, Berends MA, et al,. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2012; 26: 283-91.
6. van Lümig PP, Driessen RJ, Boezeman JB, et al,. Long-term efficacy of etanercept for psoriasis in daily practice. Br J Dermatol 2012; 166: 445-7.
7. van Lümig PP, van de Kerkhof PC, Boezeman JB, et al,. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol 2013; 27: 593-600.
8. Fernández-Torres RM, Paradela S, Fonseca E,. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatolog Treat 2013; 25: 54-6.
9. Antoniou C, Stefanaki I, Stratigos A, et al,. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol 2010; 162: 1117-23.
10. de Groot M, Appelman M, Spuls PI, et al,. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-14.
11. Esposito M, Gisondi P, Cassano N, et al,. Survival rate of anti-TNF-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666-72.
12. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
13. Brunasso AM, Puntoni M, Massone C,. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 2012; 166: 447-9.
14. Basra MK, Hussain S,. Application of the dermatology life quality index in clinical trials of biologics for psoriasis. Chin J Integr Med 2012; 18: 179-85.
15. Both H, Essink-Bot ML, Busschbach J, Nijsten T,. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726-39.
16. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
17. Prinsen CA, Lindeboom R, de Korte J,. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol 2011; 131: 1945-7.
18. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol 2013; 40: 39-42.
19. Menting SP, van Lümig PP, de Vries AC, et al,. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol 2014; 150: 130-6.
20. Bito T, Nishikawa R, Hatakeyama M, et al,. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol 2014; 170: 922-9.
21. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
22. Puig L, Lõpez A, Vilarrasa E, García I,. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2013; doi: 10.1111/jdv.12238 [Epub ahead of print].
23. van Lümig PP, Lecluse LL, Driessen RJ, et al,. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010; 163: 838-46.
24. Lecluse LL, de Groot M, Bos JD, Spuls PI,. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009; 161: 948-51.
25. Clemmensen A, Spon M, Skov L, et al,. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-40.
26. Griffiths CE, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.